Shah Rashmi, Perry Lisa, Deodhar Atul
Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Mail Code OP-09, Portland, OR 97239, USA.
Immunotherapy. 2015;7(12):1241-7. doi: 10.2217/imt.15.93. Epub 2015 Nov 23.
Ankylosing spondylitis is a chronic inflammatory disorder involving the sacroiliac joint, spine and less frequently the peripheral joints. Nonsteroidal anti-inflammatory drugs and TNF-α inhibitors are utilized to reduce signs and symptoms. Whether these agents slow disease progression, is still debatable. Secukinumab is a fully human monoclonal antibody against IL-17 that has been studied in patients with ankylosing spondylitis with promising results. It has demonstrated improvement in signs, symptoms, patient reported outcomes and functional status and has been well tolerated. The clinical improvement is also mirrored in the improvement in sacroiliac joint magnetic resonance imaging scans.
强直性脊柱炎是一种慢性炎症性疾病，累及骶髂关节、脊柱，较少累及外周关节。非甾体抗炎药和肿瘤坏死因子-α抑制剂用于减轻体征和症状。这些药物是否能减缓疾病进展仍有争议。司库奇尤单抗是一种针对白细胞介素-17的全人源单克隆抗体，已在强直性脊柱炎患者中进行研究，结果令人鼓舞。它已证明在体征、症状、患者报告的结局和功能状态方面有所改善，并且耐受性良好。骶髂关节磁共振成像扫描的改善也反映了临床改善情况。
